ALTERITY THERAPEUTICS LIMITED - Announcements

3.57%

1.4¢

Market Cap $128.9M

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

ATH	Prana announces preliminary results of Alzheimer's Trial	PRICE SENSITIVE	31/03/14	841.04KB	Share
ATH	Trading Halt	PRICE SENSITIVE	31/03/14	79.75KB	Share
ATH	Appendix 4D Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/14	2.05MB	Share
ATH	Prana Announces Successful Phase 2 Results in HD Trial	PRICE SENSITIVE	18/02/14	941.62KB	Share
ATH	Trading Halt	PRICE SENSITIVE	17/02/14	87.9KB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	03/02/14	210.49KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/14	61.01KB	Share
ATH	Prana Provides Update on PBT2 AD Extension trial	PRICE SENSITIVE	11/12/13	47.81KB	Share
ATH	Prana completes PBT2 dosing in IMAGINE AD Trial	PRICE SENSITIVE	09/12/13	94.28KB	Share
ATH	Prana Provides Update on Clinical Trials for Alzheimers	PRICE SENSITIVE	18/11/13	30.14KB	Share
ATH	Prana's PBT2 Reverses Memory Loss in Normal Aging	PRICE SENSITIVE	31/10/13	142.51KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	24/10/13	64.2KB	Share
ATH	Prana Updates Progress on PBT2 Trials	PRICE SENSITIVE	13/09/13	131.32KB	Share
ATH	Parkinsons UK Awards GBP150,000 to Study Pranas PBT434	PRICE SENSITIVE	04/09/13	32.57KB	Share
ATH	Appendix 4E Preliminary Final Report and Statutory Accounts	PRICE SENSITIVE	30/08/13	2.66MB	Share
ATH	Response to ASX price query	PRICE SENSITIVE	26/08/13	172.09KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/13	61.38KB	Share
ATH	Prana Doses 1st Patient in PBT2 Alzheimers Extension Study	PRICE SENSITIVE	29/07/13	30.03KB	Share
ATH	Prana Completes Phase 2 Huntington Disease Trial with PBT2	PRICE SENSITIVE	23/07/13	32.24KB	Share
ATH	Prana receives approval for open label extension study in AD	PRICE SENSITIVE	03/07/13	97.07KB	Share
ATH	Pranas PBT434 shows potential as treatment in PD	PRICE SENSITIVE	20/06/13	1.18MB	Share
ATH	New benchmark test to assess HD patients in clincial trials	PRICE SENSITIVE	19/06/13	527.83KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/13	60.58KB	Share
ATH	Share Purchase Plan 2013 Offer Document	PRICE SENSITIVE	11/04/13	220.56KB	Share
ATH	Prana Announces Successful A$7 milion Capital Raising	PRICE SENSITIVE	27/03/13	28.21KB	Share
ATH	Trading Halt	PRICE SENSITIVE	27/03/13	159KB	Share
ATH	Prana details PBT2 data on reduced Tau Cognitive Impairment	PRICE SENSITIVE	08/03/13	55.56KB	Share
ATH	Response to ASX Query	PRICE SENSITIVE	07/03/13	181.39KB	Share
ATH	Pranas PBT434 Inhibits PD Protein & Brain Cell Death	PRICE SENSITIVE	06/03/13	31.28KB	Share
ATH	Prana's PBT2 Reduces Tau Related Cognitive Impairment	PRICE SENSITIVE	04/03/13	29.74KB	Share
ATH	Appendix 4D	PRICE SENSITIVE	27/02/13	1.36MB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/13	59.61KB	Share
ATH	Prana Completes Recruitment in Huntington Trial	PRICE SENSITIVE	19/12/12	74.18KB	Share
ATH	Journal of Huntington's Disease Publishes Benefits of PBT2	PRICE SENSITIVE	13/12/12	76.07KB	Share
ATH	New York Academy of Sciences Symposium Discusses PBT2	PRICE SENSITIVE	06/12/12	33.18KB	Share
ATH	Prana Completes Recruitment in Alzheimer's Trial	PRICE SENSITIVE	27/11/12	31.79KB	Share
ATH	Prana Provides Huntington Disease Trial Update	PRICE SENSITIVE	14/11/12	34.22KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	29/10/12	149.16KB	Share
ATH	Prana Announces A$6.0 Million Capital Raising	PRICE SENSITIVE	01/10/12	29.24KB	Share
ATH	Trading Halt	PRICE SENSITIVE	01/10/12	94.09KB	Share
ATH	Prana Receives Recommendation to Proceed with Clinical Trial	PRICE SENSITIVE	12/09/12	197.62KB	Share
ATH	Significant Promise in the Fight Against Alzheimer's Disease	PRICE SENSITIVE	11/09/12	43.65KB	Share
ATH	Appendix 4E - Preliminary Financial Report	PRICE SENSITIVE	31/08/12	137.42KB	Share
ATH	Prana's Parkinson's drug meets development milestone	PRICE SENSITIVE	30/08/12	54.58KB	Share
ATH	Prana Provides Clinical Trials Update	PRICE SENSITIVE	22/08/12	157.9KB	Share
ATH	Appendix 4C - Quarterly report	PRICE SENSITIVE	31/07/12	58.79KB	Share
ATH	Prana's PBT2 presented at HDSA National Convention	PRICE SENSITIVE	13/06/12	226.88KB	Share
ATH	Prana Comments on Neurology Publication Huntington Data	PRICE SENSITIVE	01/05/12	205.91KB	Share
ATH	First Patient Enrolled in Phase II Huntington Disease Trial	PRICE SENSITIVE	30/04/12	187.99KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/12	57.62KB	Share
ATH	Prana Doses First Patient in the IMAGINE Phase II Trial	PRICE SENSITIVE	06/03/12	194.27KB	Share
ATH	Appendix 4D	PRICE SENSITIVE	24/02/12	854.6KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/12	58.77KB	Share
ATH	FDA Approval to Commence Huntington's Disease Clinical Trial	PRICE SENSITIVE	04/01/12	217.41KB	Share
ATH	Landmark Publication Endorses Prana's Strategy	PRICE SENSITIVE	16/12/11	219.01KB	Share
ATH	Key Patent for Parkinson's Drug PBT434 Secured in USA	PRICE SENSITIVE	28/11/11	28.6KB	Share
ATH	Prana Receives Approval For Alzheimer's Trial	PRICE SENSITIVE	22/11/11	332.05KB	Share
ATH	PBT2 reverses the loss of synaptic activity in neurons	PRICE SENSITIVE	14/11/11	181.51KB	Share
ATH	Australian Government funds study into benefits of PBT2	PRICE SENSITIVE	27/10/11	186.36KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/11	59.1KB	Share
ATH	Government Grant to Study effect of PBT2 in the ageing brain	PRICE SENSITIVE	20/10/11	231.52KB	Share
ATH	Prana's PBT2 Directly Restores Neurons Critical to Cognition	PRICE SENSITIVE	19/09/11	52.57KB	Share
ATH	Trial presented at World Congress on Huntington's Disease	PRICE SENSITIVE	12/09/11	48.23KB	Share
ATH	Appendix 4E - Preliminary Financial Report	PRICE SENSITIVE	25/08/11	121.23KB	Share
ATH	Prana Receives Michael J. Fox Foundation Grant	PRICE SENSITIVE	22/08/11	52.17KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/07/11	59.46KB	Share
ATH	Prospectus Supplement	PRICE SENSITIVE	14/07/11	194.94KB	Share
ATH	Prana Announces At-the-Market Issuance Program	PRICE SENSITIVE	14/07/11	45.27KB	Share
ATH	Quintiles Makes Second Investment in Prana	PRICE SENSITIVE	30/06/11	44.17KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/11	59.45KB	Share
ATH	Prana accelerates PBT2 commercial development	PRICE SENSITIVE	20/04/11	79.77KB	Share
ATH	Prana secures key PBT2 patent in Japan	PRICE SENSITIVE	11/04/11	80.12KB	Share
ATH	Prana's PBT2 Phase II trial receives funding from ADDF	PRICE SENSITIVE	31/03/11	60.35KB	Share
ATH	Prana Raises A$6.19 million in a Private Placement	PRICE SENSITIVE	23/03/11	45.27KB	Share
ATH	PBT2 - Directly Restores Neurons Critical to Cognition	PRICE SENSITIVE	21/03/11	49.32KB	Share
ATH	Prana's Co-Founding Scientist Awarded Prestigious Fellowship	PRICE SENSITIVE	04/03/11	45.58KB	Share
ATH	Half Yearly Report and Accounts	PRICE SENSITIVE	01/03/11	1.1MB	Share
ATH	Response to ASX Price Query	PRICE SENSITIVE	18/02/11	136.68KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/11	71.46KB	Share
ATH	Prana plans to advance Alzheimers clinical trial	PRICE SENSITIVE	08/11/10	26.08KB	Share
ATH	Trading Halt	PRICE SENSITIVE	04/11/10	49.84KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/10	62.01KB	Share
ATH	Prana selects lead PD drug candidate for development	PRICE SENSITIVE	29/09/10	31.93KB	Share
ATH	Appendix 4E for the Year Ended 30 June 2010	PRICE SENSITIVE	27/08/10	242.15KB	Share
ATH	Prana secures key PBT2 patents in the US and Europe	PRICE SENSITIVE	24/08/10	31.44KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/10	65.91KB	Share
ATH	New PBT2 data in 2010 Hot Topics Session	PRICE SENSITIVE	01/07/10	82.71KB	Share
ATH	Investment by Quintiles, Placement of 225 million Shares	PRICE SENSITIVE	28/06/10	31.25KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/10	75.25KB	Share
ATH	Prana Provides Analysis of PBT2 Therapeutic Strategy for AD	PRICE SENSITIVE	29/04/10	31.44KB	Share
ATH	Prana to commence Phase 11b trial on PBT2	PRICE SENSITIVE	20/04/10	31.12KB	Share
ATH	New Analysis of Clinical Trial published in Journal of AD	PRICE SENSITIVE	19/04/10	42.64KB	Share
ATH	Appendix 4D for the Half Year Ended 31 December 2009	PRICE SENSITIVE	25/02/10	1.04MB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/10	65.46KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/09	122.41KB	Share
ATH	Prana Secures $6 million Additional Financing	PRICE SENSITIVE	09/09/09	34.01KB	Share
ATH	Preliminary Final Report	PRICE SENSITIVE	26/08/09	223.36KB	Share
ATH	Prana Allowed Key Patent for PBT2 in the United States	PRICE SENSITIVE	12/08/09	40.4KB	Share
ATH	Prana is Granted Key Patent by European Patent Office	PRICE SENSITIVE	05/08/09	31.67KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/09	71.11KB	Share

ATHPrana announces preliminary results of Alzheimer's Trial
31/03/14	PRICE SENSITIVE	841.04KB	Share
ATHTrading Halt
31/03/14	PRICE SENSITIVE	79.75KB	Share
ATHAppendix 4D Half Yearly Report and Accounts
26/02/14	PRICE SENSITIVE	2.05MB	Share
ATHPrana Announces Successful Phase 2 Results in HD Trial
18/02/14	PRICE SENSITIVE	941.62KB	Share
ATHTrading Halt
17/02/14	PRICE SENSITIVE	87.9KB	Share
ATHResponse to ASX Price Query
03/02/14	PRICE SENSITIVE	210.49KB	Share
ATHAppendix 4C - quarterly
31/01/14	PRICE SENSITIVE	61.01KB	Share
ATHPrana Provides Update on PBT2 AD Extension trial
11/12/13	PRICE SENSITIVE	47.81KB	Share
ATHPrana completes PBT2 dosing in IMAGINE AD Trial
09/12/13	PRICE SENSITIVE	94.28KB	Share
ATHPrana Provides Update on Clinical Trials for Alzheimers
18/11/13	PRICE SENSITIVE	30.14KB	Share
ATHPrana's PBT2 Reverses Memory Loss in Normal Aging
31/10/13	PRICE SENSITIVE	142.51KB	Share
ATHAppendix 4C - quarterly
24/10/13	PRICE SENSITIVE	64.2KB	Share
ATHPrana Updates Progress on PBT2 Trials
13/09/13	PRICE SENSITIVE	131.32KB	Share
ATHParkinsons UK Awards GBP150,000 to Study Pranas PBT434
04/09/13	PRICE SENSITIVE	32.57KB	Share
ATHAppendix 4E Preliminary Final Report and Statutory Accounts
30/08/13	PRICE SENSITIVE	2.66MB	Share
ATHResponse to ASX price query
26/08/13	PRICE SENSITIVE	172.09KB	Share
ATHAppendix 4C - quarterly
31/07/13	PRICE SENSITIVE	61.38KB	Share
ATHPrana Doses 1st Patient in PBT2 Alzheimers Extension Study
29/07/13	PRICE SENSITIVE	30.03KB	Share
ATHPrana Completes Phase 2 Huntington Disease Trial with PBT2
23/07/13	PRICE SENSITIVE	32.24KB	Share
ATHPrana receives approval for open label extension study in AD
03/07/13	PRICE SENSITIVE	97.07KB	Share
ATHPranas PBT434 shows potential as treatment in PD
20/06/13	PRICE SENSITIVE	1.18MB	Share
ATHNew benchmark test to assess HD patients in clincial trials
19/06/13	PRICE SENSITIVE	527.83KB	Share
ATHAppendix 4C - quarterly
29/04/13	PRICE SENSITIVE	60.58KB	Share
ATHShare Purchase Plan 2013 Offer Document
11/04/13	PRICE SENSITIVE	220.56KB	Share
ATHPrana Announces Successful A$7 milion Capital Raising
27/03/13	PRICE SENSITIVE	28.21KB	Share
ATHTrading Halt
27/03/13	PRICE SENSITIVE	159KB	Share
ATHPrana details PBT2 data on reduced Tau Cognitive Impairment
08/03/13	PRICE SENSITIVE	55.56KB	Share
ATHResponse to ASX Query
07/03/13	PRICE SENSITIVE	181.39KB	Share
ATHPranas PBT434 Inhibits PD Protein & Brain Cell Death
06/03/13	PRICE SENSITIVE	31.28KB	Share
ATHPrana's PBT2 Reduces Tau Related Cognitive Impairment
04/03/13	PRICE SENSITIVE	29.74KB	Share
ATHAppendix 4D
27/02/13	PRICE SENSITIVE	1.36MB	Share
ATHAppendix 4C - quarterly
31/01/13	PRICE SENSITIVE	59.61KB	Share
ATHPrana Completes Recruitment in Huntington Trial
19/12/12	PRICE SENSITIVE	74.18KB	Share
ATHJournal of Huntington's Disease Publishes Benefits of PBT2
13/12/12	PRICE SENSITIVE	76.07KB	Share
ATHNew York Academy of Sciences Symposium Discusses PBT2
06/12/12	PRICE SENSITIVE	33.18KB	Share
ATHPrana Completes Recruitment in Alzheimer's Trial
27/11/12	PRICE SENSITIVE	31.79KB	Share
ATHPrana Provides Huntington Disease Trial Update
14/11/12	PRICE SENSITIVE	34.22KB	Share
ATHAppendix 4C - quarterly
29/10/12	PRICE SENSITIVE	149.16KB	Share
ATHPrana Announces A$6.0 Million Capital Raising
01/10/12	PRICE SENSITIVE	29.24KB	Share
ATHTrading Halt
01/10/12	PRICE SENSITIVE	94.09KB	Share
ATHPrana Receives Recommendation to Proceed with Clinical Trial
12/09/12	PRICE SENSITIVE	197.62KB	Share
ATHSignificant Promise in the Fight Against Alzheimer's Disease
11/09/12	PRICE SENSITIVE	43.65KB	Share
ATHAppendix 4E - Preliminary Financial Report
31/08/12	PRICE SENSITIVE	137.42KB	Share
ATHPrana's Parkinson's drug meets development milestone
30/08/12	PRICE SENSITIVE	54.58KB	Share
ATHPrana Provides Clinical Trials Update
22/08/12	PRICE SENSITIVE	157.9KB	Share
ATHAppendix 4C - Quarterly report
31/07/12	PRICE SENSITIVE	58.79KB	Share
ATHPrana's PBT2 presented at HDSA National Convention
13/06/12	PRICE SENSITIVE	226.88KB	Share
ATHPrana Comments on Neurology Publication Huntington Data
01/05/12	PRICE SENSITIVE	205.91KB	Share
ATHFirst Patient Enrolled in Phase II Huntington Disease Trial
30/04/12	PRICE SENSITIVE	187.99KB	Share
ATHAppendix 4C - quarterly
27/04/12	PRICE SENSITIVE	57.62KB	Share
ATHPrana Doses First Patient in the IMAGINE Phase II Trial
06/03/12	PRICE SENSITIVE	194.27KB	Share
ATHAppendix 4D
24/02/12	PRICE SENSITIVE	854.6KB	Share
ATHAppendix 4C - quarterly
31/01/12	PRICE SENSITIVE	58.77KB	Share
ATHFDA Approval to Commence Huntington's Disease Clinical Trial
04/01/12	PRICE SENSITIVE	217.41KB	Share
ATHLandmark Publication Endorses Prana's Strategy
16/12/11	PRICE SENSITIVE	219.01KB	Share
ATHKey Patent for Parkinson's Drug PBT434 Secured in USA
28/11/11	PRICE SENSITIVE	28.6KB	Share
ATHPrana Receives Approval For Alzheimer's Trial
22/11/11	PRICE SENSITIVE	332.05KB	Share
ATHPBT2 reverses the loss of synaptic activity in neurons
14/11/11	PRICE SENSITIVE	181.51KB	Share
ATHAustralian Government funds study into benefits of PBT2
27/10/11	PRICE SENSITIVE	186.36KB	Share
ATHAppendix 4C - quarterly
27/10/11	PRICE SENSITIVE	59.1KB	Share
ATHGovernment Grant to Study effect of PBT2 in the ageing brain
20/10/11	PRICE SENSITIVE	231.52KB	Share
ATHPrana's PBT2 Directly Restores Neurons Critical to Cognition
19/09/11	PRICE SENSITIVE	52.57KB	Share
ATHTrial presented at World Congress on Huntington's Disease
12/09/11	PRICE SENSITIVE	48.23KB	Share
ATHAppendix 4E - Preliminary Financial Report
25/08/11	PRICE SENSITIVE	121.23KB	Share
ATHPrana Receives Michael J. Fox Foundation Grant
22/08/11	PRICE SENSITIVE	52.17KB	Share
ATHAppendix 4C - quarterly
27/07/11	PRICE SENSITIVE	59.46KB	Share
ATHProspectus Supplement
14/07/11	PRICE SENSITIVE	194.94KB	Share
ATHPrana Announces At-the-Market Issuance Program
14/07/11	PRICE SENSITIVE	45.27KB	Share
ATHQuintiles Makes Second Investment in Prana
30/06/11	PRICE SENSITIVE	44.17KB	Share
ATHAppendix 4C - quarterly
28/04/11	PRICE SENSITIVE	59.45KB	Share
ATHPrana accelerates PBT2 commercial development
20/04/11	PRICE SENSITIVE	79.77KB	Share
ATHPrana secures key PBT2 patent in Japan
11/04/11	PRICE SENSITIVE	80.12KB	Share
ATHPrana's PBT2 Phase II trial receives funding from ADDF
31/03/11	PRICE SENSITIVE	60.35KB	Share
ATHPrana Raises A$6.19 million in a Private Placement
23/03/11	PRICE SENSITIVE	45.27KB	Share
ATHPBT2 - Directly Restores Neurons Critical to Cognition
21/03/11	PRICE SENSITIVE	49.32KB	Share
ATHPrana's Co-Founding Scientist Awarded Prestigious Fellowship
04/03/11	PRICE SENSITIVE	45.58KB	Share
ATHHalf Yearly Report and Accounts
01/03/11	PRICE SENSITIVE	1.1MB	Share
ATHResponse to ASX Price Query
18/02/11	PRICE SENSITIVE	136.68KB	Share
ATHAppendix 4C - quarterly
28/01/11	PRICE SENSITIVE	71.46KB	Share
ATHPrana plans to advance Alzheimers clinical trial
08/11/10	PRICE SENSITIVE	26.08KB	Share
ATHTrading Halt
04/11/10	PRICE SENSITIVE	49.84KB	Share
ATHAppendix 4C - quarterly
27/10/10	PRICE SENSITIVE	62.01KB	Share
ATHPrana selects lead PD drug candidate for development
29/09/10	PRICE SENSITIVE	31.93KB	Share
ATHAppendix 4E for the Year Ended 30 June 2010
27/08/10	PRICE SENSITIVE	242.15KB	Share
ATHPrana secures key PBT2 patents in the US and Europe
24/08/10	PRICE SENSITIVE	31.44KB	Share
ATHAppendix 4C - quarterly
30/07/10	PRICE SENSITIVE	65.91KB	Share
ATHNew PBT2 data in 2010 Hot Topics Session
01/07/10	PRICE SENSITIVE	82.71KB	Share
ATHInvestment by Quintiles, Placement of 225 million Shares
28/06/10	PRICE SENSITIVE	31.25KB	Share
ATHAppendix 4C - quarterly
30/04/10	PRICE SENSITIVE	75.25KB	Share
ATHPrana Provides Analysis of PBT2 Therapeutic Strategy for AD
29/04/10	PRICE SENSITIVE	31.44KB	Share
ATHPrana to commence Phase 11b trial on PBT2
20/04/10	PRICE SENSITIVE	31.12KB	Share
ATHNew Analysis of Clinical Trial published in Journal of AD
19/04/10	PRICE SENSITIVE	42.64KB	Share
ATHAppendix 4D for the Half Year Ended 31 December 2009
25/02/10	PRICE SENSITIVE	1.04MB	Share
ATHAppendix 4C - quarterly
29/01/10	PRICE SENSITIVE	65.46KB	Share
ATHAppendix 4C - quarterly
28/10/09	PRICE SENSITIVE	122.41KB	Share
ATHPrana Secures $6 million Additional Financing
09/09/09	PRICE SENSITIVE	34.01KB	Share
ATHPreliminary Final Report
26/08/09	PRICE SENSITIVE	223.36KB	Share
ATHPrana Allowed Key Patent for PBT2 in the United States
12/08/09	PRICE SENSITIVE	40.4KB	Share
ATHPrana is Granted Key Patent by European Patent Office
05/08/09	PRICE SENSITIVE	31.67KB	Share
ATHAppendix 4C - quarterly
30/07/09	PRICE SENSITIVE	71.11KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.4¢		Change -0.001(3.57%)		Mkt cap ! $128.9M

Open	High	Low	Value	Volume
1.4¢	1.4¢	1.4¢	$3.211K	236.5K

Buyers (Bids)

No.	Vol.	Price($)
40	21639849	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.4¢	2014025	8

View Market Depth

No.	Vol.	Price($)
2	36522	0.014
38	21571349	0.013
36	17098569	0.012
15	7706147	0.011
31	14714355	0.010

Price($)	Vol.	No.
0.014	1547234	5
0.015	21078306	12
0.016	4283104	13
0.017	7408424	11
0.018	11761167	21

Last trade - 09.59am 13/08/2025 (20 minute delay)


Last 1.4¢		Change -0.001 ( 3.85 %)
Open	High	Low	Volume
1.4¢	1.4¢	1.3¢	1614285
Last updated 10.14am 13/08/2025 ?

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available